4-butyrolactone has been researched along with thromboplastin in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Kottke-Marchant, K; Marchant, RE; Murugesan, G; Rani, MR; Ransohoff, RM | 1 |
Dai, J; Huang, J; Jiang, R; Tang, L; Tian, R; Yang, Y; Zhang, L | 1 |
2 other study(ies) available for 4-butyrolactone and thromboplastin
Article | Year |
---|---|
Endothelial cell expression of monocyte chemotactic protein-1, tissue factor, and thrombomodulin on hydrophilic plasma polymers.
Topics: 4-Butyrolactone; Base Sequence; Biocompatible Materials; Cells, Cultured; Chemokine CCL2; DNA Primers; Endothelium, Vascular; Gene Expression; Humans; Materials Testing; Povidone; RNA, Messenger; Surface Properties; Thrombomodulin; Thromboplastin; Tumor Necrosis Factor-alpha | 2000 |
The SIRT1 inhibitor EX-527 suppresses mTOR activation and alleviates acute lung injury in mice with endotoxiemia.
Topics: 4-Butyrolactone; Acute Lung Injury; Adaptor Proteins, Signal Transducing; Animals; Carbazoles; Carrier Proteins; Cell Cycle Proteins; Endotoxemia; Eukaryotic Initiation Factors; Interleukin-6; Lipopolysaccharides; Lung; Male; Mice; Mice, Inbred BALB C; Phosphoproteins; Phosphorylation; Plasminogen Activator Inhibitor 1; Sirtuin 1; Thromboplastin; TOR Serine-Threonine Kinases; Tumor Necrosis Factor-alpha | 2017 |